IL-ADVANCED-CLINICAL
Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, is pleased to announce that Dr. Andreas Amrein has joined the Executive Team as Senior Vice President of Asia-Pacific (APAC) and Japan as well as Managing Director for Europe and Canada.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220308006375/en/
Dr. Amrein will be instrumental to the organization’s continued expansion and strengthening of Advanced Clinical’s current operations into the APAC region, which include offices in Singapore, Australia and Japan. He’ll also oversee development and expansion opportunities for additional locations across Europe and Canada, complementing the company’s existing footprint inclusive of 10 office locations in Europe as well as an office in Toronto, Canada.
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies, including Fortune 100 companies (Novartis, Abbott and Shire) and dynamic start-ups.
“From my specialization in rapid commercial expansions, launches, transformations, partnerships and more across Asia and around the globe, I look forward to leveraging my knowledge to help Advanced Clinical further establish quality operations internationally,” said Dr. Amrein.
“We are excited to have Andreas on our team as we continue to expand into the APAC region and Japan,” said Julie Ross, President of Advanced Clinical. “Andreas will be instrumental in accelerating business growth as we diversify our global clinical programs and elevate our clinical strategy for the clients and patients we serve. After our successful entry into the region in 2021 combined with additional APAC office openings planned for 2022, Andreas will undoubtedly help elevate our presence across the APAC, European and Canadian regions as a global leader in clinical research, FSP and strategic resourcing services.”
About Advanced Clinical
Advanced Clinical is a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey. Our goal is to improve the lives of all those touched by clinical research – approaching each opportunity with foresight, character, resilience and innovation. Based on decades of experience, we help our clients achieve better outcomes by conducting candid conversations and anticipating potential issues through our customized solutions. Visit our website to learn more: www.advancedclinical.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006375/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 11:30:00 CET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
WEX® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 11:15:00 CET | Press release
EV drivers of any car brand using the EV Driver by WEX app can now charge at one of Europe’s largest and most reliable charging networks, benefitting from low-cost fast charging across 1,500+ locations. WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: compari
OpenAI and Capco Announce Services Partnership to Accelerate the Transformation of the Global Financial Services and Energy Sectors17.11.2025 11:00:00 CET | Press release
Global management and technology consultancy Capco, a Wipro company, has joined OpenAI’s Beta Services Partner Program, providing Capco with priority access to the very latest AI innovation. Capco and OpenAI will collaborate to solve complex client problems and deploy scalable solutions, positioning Capco as a trusted AI partner to financial services and energy clients worldwide. Through the services partnership, Capco gains early access to OpenAI’s technology, technical support, solution architects, and training resources. OpenAI will leverage Capco’s 25+ years of global transformation expertise and proven delivery experience across the financial services and energy sectors. Together, Capco and OpenAI will explore innovative solutions to tackle the most significant challenges confronting financial services and energy clients today. The opportunities for AI-led innovation are significant, ranging from enhanced product design to operational change and regulatory compliance, to employee
Global Cement Industry Reports 25% CO2 Intensity Reduction and Calls for Urgent Government Action to Accelerate Net Zero Mission17.11.2025 11:00:00 CET | Press release
GCCA launches ‘Cement and Concrete Industry Net Zero Action and Progress Report 2025/6‘. New report demonstrates decarbonisation action of global cement industry and the required government policies to accelerate net zero progress. More than 60 standout projects from across the world are featured, highlighting ongoing development of innovation and technology, deployment of carbon capture, increasing use of alternative energy sources and use of new materials. The extensive decarbonisation work being carried out by the global cement and concrete industry to cut CO₂ emissions is set out in a new global report launched at COP30 in Belem, Brazil. The report details latest industry data showing that the sector is making progress, and also emphasises the need for urgent global government input to help accelerate action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117920702/en/ GCCA Cement and Concrete Industry Net Zero Action
Convatec Selects LTIMindtree for Strategic, AI-Powered SAP S/4HANA Transformation17.11.2025 09:30:00 CET | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced its selection as a strategic partner by Convatec, a leading global medical products and technologies company, for the implementation of SAP’s Digital Core – S/4HANA. As part of this engagement, LTIMindtree will support Convatec to implement SAP’s Digital Core – S/4HANA across its Convatec’s business operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114580133/en/ Srini Rao, EVP and Chief Business Officer - Europe at LTIMindtree & Angie Goodwin, Chief Digital Information Officer at Convatec LTIMindtree will refresh Convatec’s SAP S/4HANA landscape, streamline business processes, and enable intelligent, AI-powered digital operations. The deployment will support Convatec’s goals for process standardisation and operational efficiency, forming the foundation for its next phase of strategic technology transf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom